Monday, November 21, 2011
Tonix Pharmaceuticals Holding Corp., of New York, said the FDA cleared its investigational new drug application for a comparative pharmacokinetic and bioavailability study of TNX-102, an oral formulation of cyclobenzaprine for treating fibromyalgia syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.